The significance of urinary markers in the evaluation of diabetic nephropathy

Journal of Medical Biochemistry

Volumn 27, Issue 3, 2008, Pages 376-382

  Cvetković, Tatjana ^a,b   Vlahović, Predrag ^b   Dordević, Vidosava ^a,b   Zvezdanović, Lilika ^b   Pavlović, Dušica ^a   Kocić, Gordana ^a   Sokolović, Dušan ^a  

^a Medical Faculty   (Serbia)

^b Clinical Centre   (Serbia)

Author keywords

Diabetic nephropathy; Ectoenzyme; Oxidative stress; Urine

Indexed keywords

BIOLOGICAL MARKER; CARBONYL DERIVATIVE; CREATININE; DIFFERENTIATION ANTIGEN; DIPEPTIDYL PEPTIDASE IV; FRUCTOSAMINE; GLUCOSE; MICROSOMAL AMINOPEPTIDASE; N ACETYL BETA GLUCOSAMINIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID OXIDATION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; URINALYSIS;

EID: 46749122302     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-008-0019-y     Document Type: Article

References (38)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to 2010. Diabet Med 1997; 14 (5): S1-S85.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
3. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 2000; 297: 135-44.
4. Evans LJ, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocrine Rev 2002; 23 (5): 599-622.
5. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003; 14: s254-8.
6. Jakuš V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53: 131-42.
7. Hong YC, Chia SK. Markers of diabetic nephropathy. J Diabet Complic 1998; 12: 43-60.
8. Czekalski S. How to diagnose and how to interpret microalbuminuria in the diabetic patients. Nephrol Dial Transplant 1996; 11: 1509-11.
9. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005; 54: 3274-81.
10. Bosomworth MP, Aparicio SR, Hay AWM. Urine N-acetyl-β-D- glucosaminidase - a marker of tubular damage? Nephrol Dial Transplant 1999; 14: 620-6.
11. Rustom R, Castigan M, Shenkin A, et al. Proteinuria and renal tubular damage: urinary N-acetyl-β-D-glucosaminidase and isoenzymes in dissimilar renal disease. Am J Nephrol 1998; 18: 179-85.
12. Stefanović V, Milojković M, Mitić-Zlatković M, Antić S, Ivić M, Vlahović P. Plasma and urine PC-1 activity in type 2 diabetics treated with metformin. Facta Universitatis 2001; 8: 59-62.
13. Stefanović V, Vlahović P, Ardaillou N, Ronco P, Ardaillou R. Cell surface aminopeptidase A and N activities in human glomerular epithelial cells. Kidney Int 1992; 41: 1571-80.
14. Amoscato AA, Alexander JW, Babcock GF. Surface aminopeptidase activity of human lymphocytes. Biochemical and biologic properties of intact cells. J Immunol 1989; 142: 1245-52.
15. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
16. Antczak C, De Meester I, Bauvois B. Ectopeptidases in pathophysiology. Bio Essays 2001; 23: 251-60.
17. Bauvois B. Ectopeptidases, enzymes plurifunctionnalles. Med Sci 1992; 8: 441-7.
18. Johnson NR, Metcalf AP, Baker RJ. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1982; 127: 87-95.
19. Siciarz A, Weinberger B, Witz G, Hiatt M, Hegyi T. Urinary thiobarbituric acid reacting substances as potential biomarkers of intrauterine hypoxia. Arch Pediatr Adolesc Med 2001; 155: 718-22.
20. Levine RL, Wiliams JA, Stadtman ER, Shacter E. Carbonyl assay for determination of oxidative modified proteins. Meth Enzymol 1994; 233: 46-57.
21. Horak E, Hopfer SM, Sunderman W. Spectrophotometric assay for urinary N-acetyl-β-D-glucosaminidase activity. Clin Chem 1981; 27: 1180-5.
22. Haugen HF, Skrede S. Nucleotide pyrophosphatase and phosphodiesterase. I. Organ distribution and activities in body fluids. Clin Chem 1977; 23: 1531-7.
23. Stefanović V, Vlahović P, Savić V, Ilić S, Mitić-Zlatković M. Kidney ectopeptidases in gentamicin and mercuric chloride-induced acute renal failure. Cell Physiol Biochem 1998; 8: 278-84.
24. UKPDS 33. An intensive blood glucose control policy with sulphonylureas or insulin reduces the risk of diabetic complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
25. Aksun SA, Ozmen B, Ozmen D, Parildar Z, Senol B, Habif S, et al. Serum and urinary nitric oxide in type 2 diabetes with or without microalbuminuria. Relation to glomerular hyperfiltration. J Diab Complic 2003; 17: 343-8.
26. De Zwart LL, Vermeulen NPE, Hermanns RCA, Commandeur JNM, Salemink PJM, Meerman JHN. Urinary excretion of biomarkers for radical-induced damage in rats treated with NDMA or diquat and the effects of calcium carbimide co-administration. Chem-Biol Inter 1999; 117: 151-72.
27. Chang JM, Kuo MC, Kuo HT, Chiu YW, Chen HC. Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med 2005; 146: 210-5.
28. Hermanns RCA, Zwart LL, Salemink PJM, Commandeur JNM, Vermeulen NPE, Meerman JHN. Increased urinary excretion of biomarkers for oxidative kidney damage by ferric nitrilotriacetate. Toxicol Sci 1998; 43: 241-9.
29. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas CM, Brammar CG, Lee F, Grant SL, Burrell LA, Jerums G, Osicka T. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-82.
30. Dursun E, Timur M, Dursun B, Sqleymanlar G, Ozben T. Protein oxidation in type 2 diabetic patients on hemodialysis. J Diabet Compl 2005; 19: 142-6.
31. Telci A, Cakatay U, Salman S, Satman I, Sivas A. Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res Clin Pract 2000; 50 (3): 213-23.
32. Machiguchi T, Yoshida H, Yonemoto S, Minakata T, Nomura K, Muso E, Tamura T, Sasaiama S. Does circulating erythropoietin reflect progression of IgA nephropathy? Comparison with urinary N-acetyl-β-D-glucosaminidase. Nephrol Dial Transplant 1999; 14: 635-640.
33. Morita E, Kaizu K, Uriu K, Hashimoto O, Komine N, Eto S. Clinical significance of urinary enzymes in diabetic nephropathy. J Diabetes Complications 1991; 5: 158-9.
34. Salem MA, El-Habashy SA, Saeid OM, El-Tawil MM, Tawfik PH. Urinary excretion of N-acetyl-beta-d-glucosaminidase and retinol binding protein as alternative indicators of nephropathy in patients with type 1 diabetes mellitus. Pediatr Diabetes 2002; 3: 37-41.
35. Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, D'Amico G. Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1890-6.
36. Hultberg B, Ravnskov U. The excretion of N-acetyl-β-D- glucosaminidase in glomerulonephritis. Clin Nephrol 1981; 15: 33-8.
37. Jung K, Pergande M, Schimke E, Ratzmann KP, Luis A. Urinary enzymes and low molecular mass proteins as indicators of diabetic nephropathy. Clin Chem 1988; 34: 544-7.
38. Dajak M, Ignjatović S, Majkić-Singh N. Funkcija bubrega - procena brzine glomerularne funkcije. Journal of Medical Biochemistry 2007; 26: 51-57.